PMVPHealthcare · BiotechnologyThe 5 Wall Street analysts covering PMV Pharmaceuticals, Inc. hold a median 12-month price target of $4 — +200.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores PMV Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (84): The share price has been relatively steady.
Value (18): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PMVP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +200.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 July 2026 | Ladenburg Thalmann | Assumes | Buy | $3.00 |
| 13 May 2026 | Oppenheimer | Maintains | Outperform | — |
| 20 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | Craig-Hallum | Initiates | Buy | — |
| 12 Apr 2024 | Jefferies | Initiates | Buy | — |
| 7 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Dec 2023 | Ladenburg Thalmann | Initiates | Buy | — |
| 16 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 May 2023 | Oppenheimer | Reiterates | Outperform | — |
| 20 Mar 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Mar 2023 | Oppenheimer | Maintains | Outperform | — |
| 17 Nov 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 June 2022 | Oppenheimer | Maintains | Outperform | — |
| 24 May 2022 | Goldman Sachs | Maintains | Buy | — |
| 2 Mar 2022 | Oppenheimer | Upgrade | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PMVP appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 82% of US stocks
Cheaper than 60% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 17% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PMV Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
PMV Pharmaceuticals (PMVP) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade signals increased confidence in PMVP's near-term outlook.
Why it matters — A PMVP watcher would care because the upgrade reflects improved earnings expectations that could influence how the market views the stock.
PMV Pharmaceuticals reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company is a precision oncology firm focused on developing small molecule therapies targeting p53.
Why it matters — PMVP watchers would care because the quarterly financial results and corporate update provide a routine but important update on the company's progress and financial standing.
The 5 Wall Street analysts covering PMV Pharmaceuticals, Inc. have a median 12-month price target of $4, with estimates ranging from $3 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering PMV Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PMV Pharmaceuticals, Inc. 68 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, PMV Pharmaceuticals, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (84 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +200.8% from the last close, and Ticker Nerd's factor model ranks PMV Pharmaceuticals, Inc. 68 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering PMV Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PMVP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $5 over the next 12 months.
PMV Pharmaceuticals, Inc. returned -9.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Pmv Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations.
The most recent item we track (Zacks Investment Research, 19 Aug 2026): "PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?". PMV Pharmaceuticals (PMVP) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. The upgrade signals increased confidence in PMVP's near-term outlook.
Pmv Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing small-molecule therapies that target p53 mutations. As a public entity in the biotech sector, Pmv Pharmaceuticals contributes to advancing cancer treatment by addressing these commonly mutated genes. The company's primary objective is to create therapeutic compounds that can reactivate normal p53 protein functions, thereby inhibiting tumor growth in various forms of cancer. Founded with expertise in structural biology and drug design, Pmv Pharmaceuticals operates at the intersection of innovation and precision medicine, aiming to introduce new cancer treatments with potentially significant clinical impact. The company's ongoing research and development efforts are primarily aimed at improving patient outcomes for those suffering from malignancies associated with p53 mutations, a critical unmet medical need in oncology. In the financial markets, Pmv Pharmaceuticals Inc. is a significant player within the biotechnology industry, attracting attention from investors focused on innovative cancer therapies and the broader field of genomic medicine.
CEO Dr. David H. Mack Ph.D. · 54 employees · United States · https://www.pmvpharma.com